Swiss drugmaker Novartis is entering a licensing agreement with a Chinese biotech that could be worth as much as $7.8 billion. The move follows several deals announced by pharmaceutical peers with China-based drug developers over the past two weeks. ING estimates that China will account for about one-third of new molecules in pharmaceutical companies’ global pipelines in 2026, compared with 4% in 2014. The article references NVS, NVO, AZN-GB, GSK, SMMT, XPH and IBB.